Início
Mercados
Gráficos e ideias
Algo
Notícias
Market
Corretoras
Baixar
Calendário econômico
Sinais de Negociação
Terminal web
Heatmap
Pressione
/
para pesquisar: @user, $symbol, ...
Pesquisar
Login
Criar uma conta
Português
English
Русский
中文
Español
日本語
Deutsch
한국어
Français
Italiano
Türkçe
CVKD
#4817
Cadrenal Therapeutics, Inc. Common Stock
4.7
9
USD
-4.01%
Setor:
Cuidados de saúde
Base:
USD
Moeda do lucro:
USD
Faixa diária
Faixa anual
Mudança diária
-4.01%
Mudança mensal
-35.53%
Mudança em 6 meses
-13.22%
Mudança anual
-13.22%
Fechamento anterior
4.9
9
Abrir
4.7
9
Bid
Ask
Mínimo
4.7
9
High
4.7
9
Volume
2
Mercados
Ações
Cuidados de saúde
CVKD
Abrir gráfico completo
Financials
Visão geral
Relatórios
Estatísticas
Trimestral
Ano
Valor
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
775.64 K
5 M
1.88 M
2.51 M
—
Valuation ratios
Enterprise value
—
2.22 M
17.24 M
12.99 M
84.84 M
Price to earnings ratio
—
-1.07
-1.66
-1.02
-6
Price to sales ratio
—
-12.1
—
—
—
Price to cash flow ratio
—
-2.54
-2.4
-1.07
-7.12
Price to book ratio
—
1.16
2.38
4.94
7.91
Enterprise value to EBITDA ratio
—
-0.18
-1.57
—
—
Profitability ratios
Return on assets %
-0.01
-0.98
-1.05
-3.06
-2.46
Return on equity %
0
-1.09
-1.43
-4.83
-3.57
Return on invested capital %
—
-37 K
-148.21 K
-595.73 K
—
Gross margin %
—
129.74
—
—
—
Operating margin %
—
1 031.27
—
—
—
EBITDA margin %
—
1 157.07
—
—
—
Net margin %
—
1 129.12
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
Current ratio
0.55
10.27
3.77
2.72
13.61
Inventory turnover
—
—
—
—
—
Asset turnover
—
-0.16
0
—
—
Solvency ratios
Debt to assets ratio
1.48
0
—
—
—
Debt to equity ratio
-0.21
0
—
—
—
Long term debt to total assets ratio
-0.14
-0.09
—
—
—
Long term debt to total equity ratio
0.02
-0.1
—
—
—
Per share metrics
Operating cash flow per share
—
-3.92
-6.03
-6.32
-6.51
EBIT per share
—
-9.55
-8.99
—
—
EBITDA per share
—
-9.52
-8.99
—
—
Total debt per share
—
0
—
—
—
Cash per share
—
9.34
8.2
2.01
10.72
Net current asset value per share
—
9.44
8.29
2.17
11.52
Tangible book value per share
—
8.55
6.1
1.37
8.22
Working capital per share
—
8.52
6.09
1.37
8.2
Book value per share
—
8.55
6.1
1.37
8.22
Notícias
Cadrenal registra prejuízo no 4º trimestre e conclui reunião com FDA sobre terapia para HIT
Cadrenal schedules FDA meeting for HIT drug CAD-1005
Ações da Cadrenal Therapeutics disparam com resultados de ensaio de Fase 2
Cadrenal Therapeutics stock surges on Phase 2 trial results
CAD-1005 da Cadrenal reduz coágulos sanguíneos em estudo sobre TIH
Cadrenal’s CAD-1005 shows reduction in blood clots in HIT trial
Cadrenal destaca potencial de inibidor 12-LOX para distúrbio sanguíneo
Cadrenal highlights potential of 12-LOX inhibitor for blood disorder
Cadrenal Therapeutics acquires first-in-class HIT treatment from Veralox
Cadrenal Therapeutics appoints PTC Therapeutics CMO to board
Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc.